• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小样本预测生物标志物研究中的 Cox 比例风险回归。

Cox proportional hazards regression in small studies of predictive biomarkers.

机构信息

Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Fehrbelliner Straße 39, 16816, Neuruppin, Germany.

Leibniz Centre for Agricultural Landscape Research (ZALF), Müncheberg, Germany.

出版信息

Sci Rep. 2024 Jun 20;14(1):14232. doi: 10.1038/s41598-024-64573-9.

DOI:10.1038/s41598-024-64573-9
PMID:38902269
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11190253/
Abstract

Predictive biomarkers are essential for personalized medicine since they select the best treatment for a specific patient. However, of all biomarkers that are evaluated, only few are eventually used in clinical practice. Many promising biomarkers may be erroneously abandoned because they are investigated in small studies using standard statistical techniques which can cause small sample bias or lack of power. The standard technique for failure time endpoints is Cox proportional hazards regression with a multiplicative interaction term between binary variables of biomarker and treatment. Properties of this model in small studies have not been evaluated so far, therefore we performed a simulation study to understand its small sample behavior. As a remedy, we applied a Firth correction to the score function of the Cox model and obtained confidence intervals (CI) using a profile likelihood (PL) approach. These methods are generally recommended for small studies of different design. Our results show that a Cox model estimates the biomarker-treatment interaction term and the treatment effect in one of the biomarker subgroups with bias, and overestimates their standard errors. Bias is however reduced and power is increased with Firth correction and PL CIs. Hence, the modified Cox model and PL CI should be used instead of a standard Cox model with Wald based CI in small studies of predictive biomarkers.

摘要

预测生物标志物对于个性化医学至关重要,因为它们为特定患者选择最佳治疗方法。然而,在所有评估的生物标志物中,最终只有少数用于临床实践。许多有前途的生物标志物可能会被错误地放弃,因为它们是在使用标准统计技术的小型研究中进行研究的,这可能会导致小样本偏差或缺乏效力。用于失效时间终点的标准技术是 Cox 比例风险回归,其中包含生物标志物和治疗的二进制变量之间的乘法交互项。到目前为止,尚未评估该模型在小型研究中的特性,因此我们进行了模拟研究以了解其小样本行为。作为补救措施,我们对 Cox 模型的得分函数应用了 Firth 校正,并使用似然比(PL)方法获得了置信区间(CI)。这些方法通常被推荐用于不同设计的小型研究。我们的研究结果表明,Cox 模型会以有偏差的方式估计生物标志物-治疗交互项和生物标志物亚组中的治疗效果,并高估其标准误差。但是,Firth 校正和 PL CI 可以减少偏差并提高功效。因此,在预测生物标志物的小型研究中,应使用修正的 Cox 模型和 PL CI 代替基于 Wald 的标准 Cox 模型和 CI。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be96/11190253/550aa89057b2/41598_2024_64573_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be96/11190253/0d7d13a4e6ff/41598_2024_64573_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be96/11190253/500664aa04dc/41598_2024_64573_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be96/11190253/550aa89057b2/41598_2024_64573_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be96/11190253/0d7d13a4e6ff/41598_2024_64573_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be96/11190253/500664aa04dc/41598_2024_64573_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be96/11190253/550aa89057b2/41598_2024_64573_Fig3_HTML.jpg

相似文献

1
Cox proportional hazards regression in small studies of predictive biomarkers.小样本预测生物标志物研究中的 Cox 比例风险回归。
Sci Rep. 2024 Jun 20;14(1):14232. doi: 10.1038/s41598-024-64573-9.
2
Addressing small sample size bias in multiple-biomarker trials: Inclusion of biomarker-negative patients and Firth correction.解决多生物标志物试验中的小样本量偏差:纳入生物标志物阴性患者及费思校正。
Biom J. 2018 Mar;60(2):275-287. doi: 10.1002/bimj.201600226. Epub 2017 Aug 1.
3
Penalized maximum likelihood inference under the mixture cure model in sparse data.稀疏数据下混合治愈模型的惩罚极大似然推断。
Stat Med. 2023 Jun 15;42(13):2134-2161. doi: 10.1002/sim.9715. Epub 2023 Mar 25.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
A Simulation Study Comparing Different Statistical Approaches for the Identification of Predictive Biomarkers.一种比较不同统计方法用于识别预测性生物标志物的模拟研究。
Comput Math Methods Med. 2019 Jun 13;2019:7037230. doi: 10.1155/2019/7037230. eCollection 2019.
6
Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies.在横断面基因关联研究中,Cox比例风险模型比逻辑回归模型具有更强的统计效能。
Eur J Hum Genet. 2008 Sep;16(9):1111-6. doi: 10.1038/ejhg.2008.59. Epub 2008 Apr 2.
7
Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials.在随机临床试验中,通过生物标志物与治疗的相互作用,从高维Cox模型中稳健估计预期生存概率。
BMC Med Res Methodol. 2017 May 22;17(1):83. doi: 10.1186/s12874-017-0354-0.
8
Shrinkage methods enhanced the accuracy of parameter estimation using Cox models with small number of events.收缩方法提高了使用 Cox 模型进行参数估计的准确性,Cox 模型的事件数量较少。
J Clin Epidemiol. 2013 Jul;66(7):743-51. doi: 10.1016/j.jclinepi.2013.02.002. Epub 2013 Apr 6.
9
Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.贝叶斯两步 Lasso 策略在时间事件终点个体化医学开发中的生物标志物选择。
Contemp Clin Trials. 2013 Nov;36(2):642-50. doi: 10.1016/j.cct.2013.09.009. Epub 2013 Sep 25.
10
A simulation study of finite-sample properties of marginal structural Cox proportional hazards models.边缘结构 Cox 比例风险模型有限样本性质的仿真研究。
Stat Med. 2012 Aug 30;31(19):2098-109. doi: 10.1002/sim.5317. Epub 2012 Apr 11.

引用本文的文献

1
Current Bioinformatics Tools in Precision Oncology.精准肿瘤学中的当前生物信息学工具
MedComm (2020). 2025 Jul 9;6(7):e70243. doi: 10.1002/mco2.70243. eCollection 2025 Jul.
2
Case-only analysis in small studies of predictive biomarkers.预测性生物标志物小型研究中的病例对照分析。
Sci Rep. 2025 Apr 16;15(1):13068. doi: 10.1038/s41598-025-96904-9.

本文引用的文献

1
A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer.生物标志物相关治疗异质性研究中统计方法的范围综述——以乳腺癌为例。
BMC Med Res Methodol. 2023 Jun 29;23(1):154. doi: 10.1186/s12874-023-01982-w.
2
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.含卡培他滨的辅助化疗对早期三阴性乳腺癌患者的获益和同源重组缺陷。
Br J Cancer. 2022 Jun;126(10):1401-1409. doi: 10.1038/s41416-022-01711-y. Epub 2022 Feb 5.
3
20 years of precision medicine in oncology.
肿瘤学领域20年的精准医疗
Lancet. 2021 May 15;397(10287):1781. doi: 10.1016/S0140-6736(21)01099-0.
4
Biomarker Discovery and Validation: Statistical Considerations.生物标志物的发现和验证:统计考虑。
J Thorac Oncol. 2021 Apr;16(4):537-545. doi: 10.1016/j.jtho.2021.01.1616. Epub 2021 Feb 2.
5
Personalized Medicine: Recent Progress in Cancer Therapy.个性化医疗:癌症治疗的最新进展
Cancers (Basel). 2021 Jan 11;13(2):242. doi: 10.3390/cancers13020242.
6
Using simulation studies to evaluate statistical methods.运用模拟研究评估统计方法。
Stat Med. 2019 May 20;38(11):2074-2102. doi: 10.1002/sim.8086. Epub 2019 Jan 16.
7
Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data.基于治疗效果的非参数度量和删失生存数据对治疗-协变量交互作用的推断。
Stat Med. 2016 Jul 20;35(16):2715-25. doi: 10.1002/sim.6907. Epub 2016 Feb 16.
8
Biomarker: Predictive or Prognostic?生物标志物:预测性还是预后性?
J Clin Oncol. 2015 Nov 20;33(33):3968-71. doi: 10.1200/JCO.2015.63.3651. Epub 2015 Sep 21.
9
Augmented case-only designs for randomized clinical trials with failure time endpoints.具有失效时间终点的随机临床试验的增强单纯病例设计。
Biometrics. 2016 Mar;72(1):30-8. doi: 10.1111/biom.12392. Epub 2015 Sep 8.
10
Cancer biomarker discovery and validation.癌症生物标志物的发现与验证。
Transl Cancer Res. 2015 Jun;4(3):256-269. doi: 10.3978/j.issn.2218-676X.2015.06.04.